drugset

drugset / Trial / NCT02813798

A Study to Evaluate the Effect of IV Doses of Rivipansel on Subjects With Renal Impairment and in Healthy Subjects

NCT02813798 ↗

Phase 1 Completed 28 enrolled GlycoMimetics Incorporated

Non-randomizedParallel-groupOpen-labelOther

Summary

The purpose of this study is to determine the effect of renal impairment on rivipansel.

Timeline

Start: 2016-06
Primary completion: 2018-02
Completion: 2018-02

Publications

Tammara BK, Ryan K, Plotka A, Shafer FE, Wei H, Readett D, Fang A, Korth-Bradley JM. Effect of Renal or Hepatic Impairment on the Pharmacokinetics, Safety, and Tolerability of Intravenous Rivipansel. Clin Pharmacol Drug Dev. 2020 Nov;9(8):918-928. doi: 10.1002/cpdd.842. Epub 2020 Jun 24.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Rivipansel	Small molecule	840 mg	Intravenous

Indications